Group 1 - Chengdu Xian Dao (688222.SH) announced an investment of 40 million yuan in MoSheng Intelligent Technology (Chengdu) Co., Ltd. through the Rong Chuang Xian Dao Fund, which is partially funded by the company [1] - After the investment, the Rong Chuang Xian Dao Fund will hold a 51% stake in MoSheng Intelligent, which will be included in Chengdu Xian Dao's consolidated financial statements [1] Group 2 - MoSheng Intelligent focuses on life sciences data infrastructure, AI model development, and pharmaceutical consulting services [2] - The company has three subsidiaries: MoSheng Data Science (Chengdu) Pharmaceutical Technology Co., Ltd., Hydrocarbon Data Science (Chengdu) Information Technology Co., Ltd., and MoSheng Data Science (Chongqing) Information Technology Co., Ltd. [2] - MoSheng Data Science (Chengdu) is the core platform established in 2020, specializing in data services and AI solutions in the life sciences sector, covering investment, project initiation, research and development, registration, production, sales, and medical services [2] - The company has received multiple certifications, including high-tech enterprise and provincial "specialized and innovative" enterprise [2]

Group 1 - Chengdu XianDao (688222.SH) announced an investment of 40 million yuan in MoSheng Intelligent Technology (Chengdu) Co., Ltd., through the RongChuang XianDao Fund, in which Chengdu XianDao holds a 40% stake [1] - After the investment, the RongChuang XianDao Fund will acquire a 51% stake in MoSheng Intelligent, which will be included in Chengdu XianDao's consolidated financial statements [1] Group 2 - MoSheng Intelligent focuses on comprehensive services in life sciences data infrastructure, AI model development, and pharmaceutical consulting [2] - MoSheng Intelligent has three subsidiaries: MoSheng Data Science (Chengdu) Pharmaceutical Technology Co., Ltd., Carbon Hydrogen Data Science (Chengdu) Information Technology Co., Ltd., and MoSheng Data Science (Chongqing) Information Technology Co., Ltd. [2] - MoSheng Data Science (Chengdu) is the core platform established in 2020, specializing in data services and AI solutions in the life sciences sector, covering investment, project initiation, research and development, registration, production, sales, and medical services [2] - MoSheng Data Science (Chengdu) has obtained multiple certifications, including high-tech enterprise and provincial "specialized and innovative" enterprise [2]

Core Viewpoint - Chengdu Xian Dao (688222.SH) announced its participation in establishing the Rong Chuang Xian Dao Fund, which will invest 40 million yuan in Mo Shang Intelligent, acquiring a 51% stake and becoming its controlling shareholder [2] Group 1: Investment Details - The Rong Chuang Xian Dao Fund will use its own funds of 40 million yuan to increase capital in Mo Shang Intelligent, subscribing to its newly registered capital of 624.4898 thousand yuan [2] - After the capital increase, the Rong Chuang Xian Dao Fund will hold a 51% equity stake in Mo Shang Intelligent [2] Group 2: Company Operations - Mo Shang Intelligent focuses on comprehensive services in life science data infrastructure, AI model development, and pharmaceutical consulting services [2]

证券代码：688222 证券简称：成都先导 公告编号：2025-056 成都先导药物开发股份有限公司 关于对外投资的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 交易实施尚需履行的审批及其他相关程序 本次对外投资事项已经公司第三届董事会第三次会议、第三届董事会战略与 可持续发展委员会第一次会议审议通过，根据《上海证券交易所科创板股票上市 规则》（以下简称《" 上市规则》"）《成都先导药物开发股份有限公司章程》（以下 简称《" 公司章程》"）等规定，本次交易无需提交股东会审议。 其它需要提醒投资者重点关注的风险事项 投资标的：摩熵智能技术（成都）有限公司（以下简称"摩熵智能"或 "目标公司"或"标的公司"）； 投资金额：本次对外投资由成都先导药物开发股份有限公司（以下简称 "成都先导"或"公司"）合并报表范围内的成都蓉创先导股权投资基 金合伙企业（有限合伙）（以下简称"蓉创先导基金"）作为投资主体使 用自有资金 4,000 万元向目标公司进行增资，认购其新增注册资本 624.4898 万元。本次增资完成后 ...

成都先导公告，使用自有资金4000万元向摩熵智能增资，认购其新增注册资本624.49万元。增资完成 后，蓉创先导基金将取得目标公司51%股权，成为目标公司控股股东。 ...

南财智讯12月19日电，成都先导公告，公司合并报表范围内的成都蓉创先导股权投资基金合伙企业（有 限合伙）使用自有资金4,000.00万元向摩熵智能技术（成都）有限公司进行增资，认购其新增注册资本 624.49万元。本次增资完成后，蓉创先导基金将持有目标公司51%股权，取得其控制权，并纳入公司合 并报表范围。本次交易不构成关联交易，亦不构成重大资产重组。 ...

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 从资金流向上来看，当日医疗服务板块主力资金净流出4.95亿元，游资资金净流出1823.62万元，散户资 金净流入5.13亿元。医疗服务板块个股资金流向见下表： 证券之星消息，12月19日医疗服务板块较上一交易日上涨1.6%，成都先导领涨。当日上证指数报收于 3890.45，上涨0.36%。深证成指报收于13140.22，上涨0.66%。医疗服务板块个股涨跌见下表： ...

Core Viewpoint - The A-share market shows positive momentum with the Shanghai Composite Index closing at 3890.45 points, above the half-year line, reflecting a gain of 0.36% and a total trading volume of 1.748742 trillion yuan [1] Group 1: Market Performance - The Shanghai Composite Index closed at 3890.45 points, above the half-year line, with a gain of 0.36% [1] - Total trading volume in the A-share market reached 1.748742 trillion yuan [1] Group 2: Stocks Breaking Half-Year Line - A total of 266 A-shares have surpassed the half-year line, indicating strong market interest [1] - Notable stocks with significant deviation rates include: - GQY Vision (10.23%) - Hongwei Technology (9.84%) - Zhongwang Fabric (8.75%) [1] Group 3: Detailed Stock Data - GQY Vision: Today's price increased by 11.23% with a turnover rate of 13.78%, latest price at 7.23 yuan [1] - Hongwei Technology: Today's price increased by 12.30% with a turnover rate of 17.12%, latest price at 27.49 yuan [1] - Zhongwang Fabric: Today's price increased by 9.98% with a turnover rate of 1.78%, latest price at 25.78 yuan [1]

Group 1 - The Shanghai Composite Index closed at 3887.81 points, above the six-month moving average, with a gain of 0.30% [1] - The total trading volume of A-shares reached 1,390.087 billion yuan [1] - A total of 249 A-shares have surpassed the six-month moving average, with notable stocks including GQY Vision, Hongwei Technology, and Zhongwang Fabric, showing significant deviation rates of 12.05%, 9.88%, and 8.75% respectively [1] Group 2 - GQY Vision (300076) had a daily increase of 13.08% with a turnover rate of 10.52%, and its latest price was 7.35 yuan, showing a deviation rate of 12.05% [1] - Hongwei Technology (688711) increased by 12.34% with a turnover rate of 15.68%, latest price at 27.50 yuan, and a deviation rate of 9.88% [1] - Zhongwang Fabric (605003) rose by 9.98% with a turnover rate of 1.76%, latest price at 25.78 yuan, and a deviation rate of 8.75% [1]

Group 1 - The core viewpoint of the news highlights a significant increase in the Shanghai Stock Exchange's Sci-Tech Innovation Board Innovative Drug Index, with a rise of 3.26% as of December 19, 2025, driven by strong performances from constituent stocks such as Chengdu Xian Dao (up 10.44%) and Yifang Bio (up 9.82%) [1] - The recent announcement by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security regarding the 2025 National Basic Medical Insurance Drug List includes 114 new drugs, of which 50 are innovative drugs, marking an 88% success rate, a 12 percentage point increase from 2024 [3] - The total R&D investment by innovative drug companies on the Sci-Tech Innovation Board reached a new high in the first three quarters of 2025, with a year-on-year increase of over 10% and an R&D intensity of 42%, significantly surpassing the overall level of A-shares [4] Group 2 - The collaboration between Innovent Biologics and Takeda Pharmaceutical regarding three innovative cancer drugs has been completed, with Innovent receiving a total upfront payment of $1.2 billion, including a strategic investment of $100 million, and potential milestone payments of up to $10.2 billion [5] - The CXO industry is entering a new high prosperity cycle, driven by external improvements, including overseas interest rate cuts and domestic recovery, with a focus on innovative drug companies benefiting from policy support and innovation upgrades [6] - The implementation of the "Medicare + Commercial Insurance" multi-layered medical security system is seen as a substantial breakthrough, with nearly 90% of new drugs approved by Sci-Tech Board biopharmaceutical companies included in the insurance list [3][4]